News

Detail published for £50 million clinical DESs

05-Sep-08

NHS Employers and the GPC have confirmed and published the final guidance on the five clinical directed enhanced services (DESs) for GPs in England.

Practices will receive £35 per patient treated under the heart failure DES, £2.33 for each newly registered patient that has been screened for alcohol misuse and 5.6p for every registered patient on the ethnicity DES.

Additionally, £588.21 will be available per practice for diagnosing and prescribing secondary prevention for patients with osteoporosis and £100 per practice for every health check for learning disabilities.

Andrew Clapperton, head of primary care contracting at NHS Employers, said: ‘We are pleased that guidance on the five new DESs for 2008/9 has now been agreed and published.’

GPC chairman Dr Laurence Buckman, added: ‘We are pleased that his guidance has been finalised so that GPs can plan how their practices are going to work with these new enhanced services.’

The DoH is now in the process of drafting the legal documentation for the five clinical DESs.

The final guidance can be found at www.nhsemployers.org/pay-conditions

sanjay.tanday@haymarket.com

Comment below and tell us what you think

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?

Quick search - use * for an abbreviated search, eg nico*

 
 

Healthcare Republic Forums

 

Quick search - use * for an abbreviated search, eg nico*

 
 

Latest Clinical Articles

Clinical Review - Renal colic

Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more

Clinical Review - Stroke

By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more

Sjogren's syndrome

Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more

Show all clinical articles

MIMS Product News

New drug - Intelence

Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more

New drug - Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more

Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more

Jobs